HOME > BUSINESS
BUSINESS
- Maruho Establishes US Subsidiary
October 3, 2011
- Ono: Corebeta for Inj. 12.5 mg for Improving Image Quality in Coronary CT Angiography
October 3, 2011
- Novartis Pharma: COPD Treatment Onbrez Inhalation Capsules
October 3, 2011
- Nesina Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
October 3, 2011
- Toyobo Biologics Partners with Catalent to Strengthen Contract Manufacturing Business
October 3, 2011
- MSD, Hisamitsu to Terminate Copromotion of Fosamac in February 2012
October 3, 2011
- Barclays Raises MTPC’s Target Share Price on Telavic Survey
October 3, 2011
- Support of Gov’t, Industry Essential for Development of RNA-based Drugs: PMRJ Seminar
October 3, 2011
- SGLT2 Inhibitor Ipragliflozin Significantly Reduced HbA1c in PIII Study: Astellas
October 3, 2011
- Weight Gain with Lantus Lowest in Patients with HbA1c Below 8%: Sanofi
October 3, 2011
- NBI, Eli Lilly Japan: DPP-4 Inhibitor Trazenta Tablets 5 mg for Type 2 Diabetes
October 3, 2011
- Taiho: CTCL Treatment Zolinza Capsules 100 mg
October 3, 2011
- Pain Treatment at Turning Point with Advent of Lyrica
October 3, 2011
- Takeda: Type 2 Diabetes Treatment Liovel LD and HD
October 3, 2011
- GE Drug Makers Will Need Flexibility to Survive Shift to Biosimilars: Mr Matsubara of Office Medisearch
October 3, 2011
- Afinitor Significantly Increased PFS in Women with Advanced Breast Cancer: Novartis
October 3, 2011
- Asahi Kasei Pharma, tella Announce Joint R&D Agreement for Cell Processing Equipment
October 3, 2011
- Pfizer Starts New Online Promotion with MedPeer
September 30, 2011
- MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars
September 30, 2011
- Takeda Files NDA for Hyperlipidemia Treatment TAK-085 in Japan
September 30, 2011
ページ
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…